Is either Dihexa or P21 FDA-approved?

No. Dihexa is not an approved drug; sold online as an unregulated research chemical. P21 is sold as an unapproved research chemical; not approved anywhere and untested in humans.

Which has stronger human evidence, Dihexa or P21?

Neither. Both are graded preclinical / minimal, with little or no controlled human outcome data for the marketed use. The key source for Dihexa is Benoist, J Pharmacol Exp Ther 2014; for P21, it is Kazim, Neurobiol Dis 2014.

What are the main safety concerns with Dihexa and P21?

Dihexa has no human safety data; activates c-Met, a growth pathway, raising theoretical cancer concerns. P21 has no human safety data; vial contents and dose are unverified.

Head-to-head

Dihexa vs P21

Two preclinical nootropic peptides with no human trials at all. The only real difference is which unanswered question is bigger: safety, or what is actually in the vial.

By Julian RothResearch & dataUpdated October 2026

Short answer

Dihexa and P21 are both graded preclinical / minimal, which leaves little or no controlled human data to choose between them. Dihexa is the one sold for cognition and memory, while P21 targets cognition and neurogenesis. Both are sold gray-market as research chemicals.

Dihexa

Preclinical / minimal

Builds synapses potently in animals, but there are no human trials — and its c-Met growth-pathway mechanism raises unanswered safety questions.

Full Dihexa evidence review

P21

P021

Preclinical / minimal

A CNTF-derived peptide that boosts neurogenesis in rodents; no human trials, no approval, and a genuinely muddled name.

Full P21 evidence review

Dihexa vs P21: head to head

FDA status / approved use: Dihexa
Not an approved drug; sold online as an unregulated research chemical
P21
Sold as an unapproved research chemical; not approved anywhere and untested in humans
Marketed for: Dihexa
Cognition, memory
P21
Cognition, neurogenesis
Outcome areas: Dihexa
Cognitive function / memory
P21
Cognitive function / memory
Evidence grade: Dihexa
Preclinical / minimal
P21
Preclinical / minimal
How it works: Dihexa
Activates the HGF/c-Met system to promote new synapse formation
P21
CNTF-derived peptide reported in rodents to raise BDNF by inhibiting LIF signaling
Route and dosing: Dihexa
Oral pill; no established human dose
P21
Not established
Headline human result: Dihexa
Not established
P21
Not established
Strongest evidence: Dihexa
Benoist, J Pharmacol Exp Ther 2014. Little or no controlled human outcome data for the marketed useDihexa evidence reviewPubMed 25187433
P21
Kazim, Neurobiol Dis 2014. Little or no controlled human outcome data for the marketed useP21 evidence reviewPubMed 25046994
Key safety signal: Dihexa
No human safety data; activates c-Met, a growth pathway, raising theoretical cancer concerns
P21
No human safety data; vial contents and dose are unverified
How it is obtained: Dihexa
Sold gray-market as a research chemical; no approved or legitimately compounded human product
P21
Sold gray-market as a research chemical; no approved or legitimately compounded human product

	Dihexa	P21
FDA status / approved use	Not an approved drug; sold online as an unregulated research chemical	Sold as an unapproved research chemical; not approved anywhere and untested in humans
Marketed for	Cognition, memory	Cognition, neurogenesis
Outcome areas	Cognitive function / memory	Cognitive function / memory
Evidence grade	Preclinical / minimal	Preclinical / minimal
How it works	Activates the HGF/c-Met system to promote new synapse formation	CNTF-derived peptide reported in rodents to raise BDNF by inhibiting LIF signaling
Route and dosing	Oral pill; no established human dose	Not established
Headline human result	Not established	Not established
Strongest evidence	Benoist, J Pharmacol Exp Ther 2014. Little or no controlled human outcome data for the marketed useDihexa evidence reviewPubMed 25187433	Kazim, Neurobiol Dis 2014. Little or no controlled human outcome data for the marketed useP21 evidence reviewPubMed 25046994
Key safety signal	No human safety data; activates c-Met, a growth pathway, raising theoretical cancer concerns	No human safety data; vial contents and dose are unverified
How it is obtained	Sold gray-market as a research chemical; no approved or legitimately compounded human product	Sold gray-market as a research chemical; no approved or legitimately compounded human product

marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.

Preclinical / minimal:: Evidence is largely animal, in-vitro, or anecdotal. Little or no controlled human outcome data for the marketed use.

Our verdict

Neither has been given to people in a published clinical trial, so there is no human efficacy data, no established dose, and no human safety profile for either, and neither is approved anywhere. Dihexa's rodent and cell-culture data are striking, but its mechanism deliberately activates the HGF/c-Met growth pathway, which is an open safety question rather than a documented harm. P21's animal data come almost entirely from one research program, and the name is genuinely ambiguous, since 'P21' collides with the unrelated cell-cycle protein CDKN1A and vendors use 'P21' and 'P021' interchangeably. Both are research-only chemicals, and no head-to-head work exists.

Dihexa fits if

Dihexa is the one to follow if synaptogenesis and the angiotensin IV literature interest you, with the c-Met caveat front of mind.

P21 fits if

P21 is the one to follow if hippocampal neurogenesis and CNTF-derived neurotrophic mimetics are the thread, provided you know it means P021.

Dihexa vs P21: common questions

Is either Dihexa or P21 FDA-approved?: No. Dihexa is not an approved drug; sold online as an unregulated research chemical. P21 is sold as an unapproved research chemical; not approved anywhere and untested in humans.
Which has stronger human evidence, Dihexa or P21?: Neither. Both are graded preclinical / minimal, with little or no controlled human outcome data for the marketed use. The key source for Dihexa is Benoist, J Pharmacol Exp Ther 2014; for P21, it is Kazim, Neurobiol Dis 2014.
What are the main safety concerns with Dihexa and P21?: Dihexa has no human safety data; activates c-Met, a growth pathway, raising theoretical cancer concerns. P21 has no human safety data; vial contents and dose are unverified.

Key studies behind each

Dihexa

Wright JW, Harding JW. (2015). The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases. Prog Neurobiol. PubMed 25455861
Benoist CC, Kawas LH, Zhu M, et al. (2014). The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met system. J Pharmacol Exp Ther. PubMed 25187433
Wright JW, Kawas LH, Harding JW. (2015). The brain hepatocyte growth factor/c-Met receptor system: a new target for the treatment of Alzheimer's disease. J Alzheimers Dis. PubMed 25649658
Ho JK, Nation DA. (2018). Cognitive benefits of angiotensin IV and angiotensin-(1-7): A systematic review of experimental studies. Neurosci Biobehav Rev. PubMed 29733881

P21

Kazim SF, Iqbal K. (2016). Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer's disease. Mol Neurodegener. PubMed 27400746
Bolognin S, Buffelli M, Puoliväli J, et al. (2014). Rescue of cognitive-aging by administration of a neurogenic and/or neurotrophic compound. Neurobiol Aging. PubMed 24702821
Kazim SF, Blanchard J, Dai CL, et al. (2014). Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease. Neurobiol Dis. PubMed 25046994
Baazaoui N, Iqbal K. (2017). Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound. Alzheimers Res Ther. PubMed 28655344

The full evidence reviews

Dihexa: a striking preclinical nootropic with zero human evidence
An orally-active angiotensin-IV–derived compound famous for building synapses “more potently than BDNF” in the lab. The animal data are real — but there are no human trials, and its c-Met growth-pathway mechanism raises unanswered safety questions.
Updated August 2026
P21 (P021): a neurogenic peptide with real animal data and no human evidence
Marketed as “P21,” the compound is really P021 — a CNTF-derived peptide that boosts neurogenesis in rodents. There are no human trials, no approval, and a genuinely muddled name. A straight read of where the science stands.
Updated August 2026

Where to get it

Where to get peptide therapy

Clinician-led telehealth services that prescribe compounded peptides. The specific peptides offered vary by provider — confirm Dihexa availability before ordering.

Disclosure: Aminoscope is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. Partners are listed first; a commission never changes what we write about a provider. How we make money.

Compare all 204 peptide-therapy providers →

Provider reviews we publish: RNK HealthSunlightTMatesRxPepsDirectRxSaludableRylo Health

Related comparisons

Dihexa vs Semax